D68.029
BillableVon Willebrand disease, type 2, unspecified
Last updated: FY2026 ICD-10-CM (Oct 1, 2025 – Sep 30, 2026) | CMS-HCC V28 (100% phase-in, PY2026)
Is D68.029 an HCC code?
Yes. D68.029 maps to Von Willebrand Disease and Other Coagulation Defects under the CMS-HCC V28 risk adjustment model (and Coagulation Defects and Other Specified Hematological Disorders under V24).
HCC Category Mapping
RAF weights shown are the community, non-dual, aged base weights from the CMS risk adjustment model file. Actual per-patient RAF contribution depends on member segment, interactions, and the model year used by the payer. V28 is the CMS-HCC model phased in over payment years 2024–2026; V24 remains in use during the transition and for historical data.
MEAT Criteria for D68.029
For D68.029 to count as a valid HCC diagnosis in a given encounter, the provider's documentation must show MEAT: Monitor, Evaluate, Assess, or Treat. A diagnosis from a prior year does not carry forward automatically — it has to be re-documented and supported each calendar year.
- MMonitor: signs, symptoms, disease progression, or lab trending documented in the note
- EEvaluate: test results, medication response, or physical findings reviewed by the provider
- AAssess: explicit mention in the assessment or plan with acknowledgment of status
- TTreat: medication, referral, procedure, therapy, or counseling tied to the diagnosis
Only one of M/E/A/T is required to support the code, but the documentation must be specific enough to show that the provider actually addressed D68.029 during that encounter — not just copy-forwarded from a problem list.
What This Code Means
D68.029 is the ICD-10-CM diagnosis code for von willebrand disease, type 2, unspecified. A bleeding disorder caused by abnormal von Willebrand factor protein (type 2), but the specific subtype is not specified or documented. D68.029 sits in the ICD-10-CM chapter for diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism (d50-d89), within the section covering coagulation defects, purpura and other hemorrhagic conditions (d65-d69).
Under the CMS-HCC V28 risk adjustment model, D68.029 maps to Von Willebrand Disease and Other Coagulation Defects (HCC 112) with a community, non-dual, aged base RAF weight of 0.247. Under the older CMS-HCC V24 model, D68.029 maps to Coagulation Defects and Other Specified Hematological Disorders (HCC 48) with a community, non-dual, aged base RAF weight of 0.209. V28 is the CMS-HCC risk adjustment model that reached 100% phase-in for payment year 2026, replacing V24 which was used during the PY2024–PY2025 transition.
Use this code only when type 2 is confirmed but the specific variant (2A, 2B, 2M, 2N) cannot be determined from documentation. Because D68.029 maps to a payment HCC, the provider's documentation must satisfy MEAT criteria (Monitor, Evaluate, Assess, or Treat) for the encounter to count toward the patient's Medicare Advantage risk adjustment score. When documentation is ambiguous, coders should issue a provider query rather than assume the highest-specificity variant.
HCC Buddy maintains structured V28 and V24 mapping, RAF weights, and MEAT documentation criteria for D68.029 sourced directly from the CMS-HCC risk adjustment model files and the CMS ICD-10-CM code set.
Coding Tips
- •Use this code only when type 2 is confirmed but the specific variant (2A, 2B, 2M, 2N) cannot be determined from documentation
- •Query the provider if additional testing results are available to specify the exact type 2 variant
Clinical Significance
Von Willebrand disease type 2, unspecified, captures cases where Type 2 VWD has been diagnosed through qualitative VWF defects but the specific subtype (2A, 2B, 2M, or 2N) has not been determined. Type 2 variants collectively account for approximately 20-25% of all VWD cases and generally present with more clinically significant bleeding than Type 1.
Documentation Requirements
- ✓Document VWF testing showing qualitative defect (disproportionate activity-to-antigen ratio), multimer analysis if available, and factor VIII levels.
- ✓Record current bleeding severity and treatment approach.
- ✓Query the provider to determine the specific subtype when additional testing has been performed.